Mengis Capital Management Inc. Boosts Stock Holdings in Pfizer Inc. (NYSE:PFE)

Mengis Capital Management Inc. raised its holdings in Pfizer Inc. (NYSE:PFE) by 1.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 77,106 shares of the biopharmaceutical company’s stock after purchasing an additional 895 shares during the period. Mengis Capital Management Inc.’s holdings in Pfizer were worth $2,770,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Nuveen Asset Management LLC grew its stake in Pfizer by 2,240.5% during the second quarter. Nuveen Asset Management LLC now owns 36,086,254 shares of the biopharmaceutical company’s stock valued at $1,563,256,000 after acquiring an additional 34,544,423 shares in the last quarter. Natixis purchased a new position in Pfizer in the 2nd quarter worth approximately $258,466,000. Invesco Ltd. grew its stake in Pfizer by 14.6% in the 2nd quarter. Invesco Ltd. now owns 21,118,606 shares of the biopharmaceutical company’s stock worth $914,857,000 after buying an additional 2,693,349 shares in the last quarter. DNB Asset Management AS grew its stake in Pfizer by 241.0% in the 3rd quarter. DNB Asset Management AS now owns 3,734,044 shares of the biopharmaceutical company’s stock worth $134,164,000 after buying an additional 2,638,873 shares in the last quarter. Finally, Thoroughbred Financial Services LLC grew its stake in Pfizer by 4,297.8% in the 2nd quarter. Thoroughbred Financial Services LLC now owns 2,656,678 shares of the biopharmaceutical company’s stock worth $265,668,000 after buying an additional 2,596,269 shares in the last quarter. 71.52% of the stock is owned by institutional investors.

PFE has been the subject of a number of research reports. ValuEngine raised shares of Pfizer from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. Morgan Stanley cut their price target on shares of Pfizer from $40.00 to $38.00 and set an “equal weight” rating for the company in a research note on Tuesday, August 27th. Zacks Investment Research raised shares of Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price target for the company in a research note on Tuesday, October 1st. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Pfizer in a research note on Tuesday, October 29th. Finally, Bank of America initiated coverage on shares of Pfizer in a research note on Wednesday, October 16th. They issued a “neutral” rating and a $37.00 price target for the company. Nine analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $44.02.

Shares of PFE traded down $0.12 during mid-day trading on Monday, reaching $36.93. The company’s stock had a trading volume of 11,861,527 shares, compared to its average volume of 23,314,186. The stock has a market cap of $207.30 billion, a PE ratio of 12.31, a P/E/G ratio of 2.11 and a beta of 0.67. The company has a current ratio of 1.47, a quick ratio of 1.21 and a debt-to-equity ratio of 0.60. Pfizer Inc. has a 52 week low of $33.97 and a 52 week high of $46.47. The company’s fifty day moving average price is $36.62 and its two-hundred day moving average price is $39.26.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.62 by $0.13. The firm had revenue of $12.68 billion during the quarter, compared to analyst estimates of $12.37 billion. Pfizer had a net margin of 30.57% and a return on equity of 28.61%. The business’s quarterly revenue was down 4.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.78 EPS. Research analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a $0.36 dividend. The ex-dividend date of this dividend is Thursday, November 7th. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.90%. Pfizer’s payout ratio is 48.00%.

In other Pfizer news, major shareholder Pfizer Inc acquired 50,000 shares of the stock in a transaction dated Tuesday, September 17th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $900,000.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Scott Gottlieb acquired 3,000 shares of the stock in a transaction dated Friday, August 23rd. The stock was acquired at an average price of $34.72 per share, with a total value of $104,160.00. Following the completion of the acquisition, the director now owns 3,000 shares in the company, valued at approximately $104,160. The disclosure for this purchase can be found here. Insiders own 0.09% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Story: Conference Calls and Individual Investors

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.